Timing of immune checkpoint blockade shapes anti-tumor immunity via a clock-dependent chemokine axis
Lichterman, J. N.; Srinivasan, T.; Wang, R.; Dende, C.; Zarek, C.; Ramirez, J. I.; Park, N.; Wang, H.; Li, W.; Kim, J.; Coughlin, L.; Poulides, N.; Sabaeifard, P.; Palmer, S. N.; Morrill, A. C.; Hassell, B.; Shelton, J. M.; Li, X. V.; Evers, B. M. M.; Zhan, X.; Takahashi, J. S.; Hooper, L. V.; Koh, A. Y.
Show abstract
Circadian clocks regulate immunity, yet how they shape the tumor immune microenvironment and influence cancer immunotherapy remains unclear. Here, we show that tumor immune infiltration and immune checkpoint inhibitor efficacy vary by time of day in mice, driven by intrinsic clocks in dendritic cells and CD8+ T cells. Time-of-day modulates the abundance, spatial organization, and cytokine-chemokine production of tumor-infiltrating immune cells. Mechanistically, dendritic cell clocks control expression of Cx3cl1, driving recruitment of CX3CR1+CD8+ T cells and thereby reshaping the tumor immune microenvironment to enhance immunotherapy efficacy. Disruption of this axis abolishes time-of-day-dependent differences in treatment response. These findings identify a circadian mechanism of immune cell recruitment to tumors and provide mechanistic insight into clinical observations linking treatment timing to immunotherapy outcomes. One sentence summaryTime of day determines cancer immunotherapy efficacy through a circadian clock-dependent chemokine axis.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immune checkpoint blockade induces gut microbiota translocation that augments extraintestinal anti-tumor immunity 96%
- Distinct CD8+ T Cell Programming in the Tumor Microenvironment Contributes to Sex Bias in Bladder Cancer Outcome 96%
- Fate-mapping lymphocyte clones and their progenies from induced antigen-signals identifies temporospatial behaviours of T cells mediating tolerance 95%
Similar papers in this journal
- TET2 regulates early and late transitions in exhausted CD8+ T-cell differentiation and limits CAR T-cell function 94%
- Therapeutic KRASG12C inhibition drives effective interferon-mediated anti-tumour immunity in immunogenic lung cancers 94%
- 1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer 94%
Similar papers in this journal
- NFAT5 induction by the tumor microenvironment enforces CD8 T cell exhaustion 96%
- Loss of the intracellular enzyme QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity 95%
- Terminal differentiation and persistence of effector regulatory T cells essential for the prevention of intestinal inflammation 95%
Similar papers in this journal
- Soluble CTLA-4 mainly produced by Treg cells inhibits type 1 inflammation without hindering type 2 immunity to allow for inflammation resolution 95%
- Opposing effects of pre-existing antibody and memory T cell help on the dynamics of recall germinal centers 94%
- IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.